S7067

SB 202190

≥98% (HPLC)

• Synonym(s): 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole
• Empirical Formula (Hill Notation): C₂₀H₁₄FN₃O
• CAS Number: 152121-30-7
• Molecular Weight: 331.34
• MDL number: MFCD00941964
• PubChem Substance ID: 24278272
• NACRES: NA.77

Properties

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: faintly yellow, to beige
• solubility: DMSO: 10 mg/mL, clear
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• SMILES string: Oc1ccc(cc1)-c2nc(-c3ccc(F)cc3)c([nH]2)-c4ccncc4
• InChI: 1S/C20H14FN3O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15/h1-12,25H,(H,23,24)
• InChI key: QHKYPYXTTXKZST-UHFFFAOYSA-N
• Gene Information: human ... MAPK14(1432)

Description

Application

SB 202190 was used to inhibit p38 activation in MCF7 cells⁵, mouse macrophages⁶ and HepG2 cells.⁷

Packaging

5, 25 mg in glass bottle

Biochem/physiol Actions

SB 202190 is a highly selective, potent and cell permeable inhibitor of p38 MAP kinase. SB 202190 binds within the ATP pocket of the active kinase (K_d = 38 nM, as measured in recombinant human p38), and selectively inhibits the p38α and β isoforms.

Features and Benefits

This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from Glaxo­Smith­Kline

Safety Information

• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves